arsenic trioxide has been researched along with ascorbic acid in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 31 (55.36) | 29.6817 |
| 2010's | 21 (37.50) | 24.3611 |
| 2020's | 3 (5.36) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dai, J; Jing, Y; Waxman, S; Weinberg, RS | 1 |
| Bachleitner-Hofmann, T; Gisslinger, B; Gisslinger, H; Grumbeck, E | 1 |
| Bahlis, NJ; Boise, LH; Dalton, WS; Grad, JM; Oshiro, MM; Reis, I | 1 |
| Chopin, M; Dombret, H; Pierron, G; Poupon, J; Raffoux, E; Récher, C; Sigaux, F; Stern, MH | 1 |
| Gao, F; Li, H; Shi, G; Shi, X; Tang, X; Wang, Z; Yi, J | 1 |
| Deb, DK; Kalvakolanu, DV; Kambhampati, S; Minucci, S; Mohindru, M; Platanias, LC; Ravandi, F; Sassano, A; Verma, A | 1 |
| Dalton, WS | 1 |
| Bahlis, NJ; Boise, LH; Eckman, J; Fernandez, HF; Goodman, M; Jordan-McMurry, I; Kharfan-Dabaja, M; Lee, KP; McCafferty-Grad, J; Neil, J; Reis, I | 1 |
| Ravandi, F; van Besien, K | 1 |
| Bachelez, H; Degos, L; Dombret, H; Dubertret, L; Dupuy, A; Jean-Louis, F; Michel, L; Musette, P; Poupon, J; Sors, A; Viguier, M | 1 |
| Hahm, ER; Han, SS; Jung, CW; Kim, K; Kim, WS; Kimler, BF; Lee, JH; Lee, MH; Lee, SJ; Park, CH; Park, HK; Park, K; Park, S; Riordan, HD; Riordan, NH; Surh, YJ; Yang, JH; Yoon, SS | 1 |
| Berenson, JR; Ferretti, D; Purner, MB; Swift, RA | 1 |
| Berenson, JR; Borad, MJ; Swift, R | 1 |
| Sekeres, MA | 1 |
| Engel, RH; Evens, AM | 1 |
| Abou-Jawde, RM; Andresen, S; Baz, R; Hussein, M; Karam, MA; Kelly, M; Reed, J; Walker, E | 1 |
| Fu, Q; Hu, BR; Li, JJ; Li, Y; Ming, ZY; Qian, JQ; Tang, Q; Xiang, JZ | 1 |
| Gokhalé, P; Morrison, MJ; Patel, T; Vissers, MC | 1 |
| Berenson, JR; Bessudo, A; Boccia, R; Bozdech, M; Ferretti, D; Flam, M; Jilani, S; Louie, R; Lutzky, J; Moss, R; Patel, R; Russell, K; Siegel, D; Stadtmauer, E; Steis, R; Swift, RA; Talisman Pomeroy, J; Volk, J; Wong, SF; Yeh, HS | 1 |
| Amadori, S; Beksac, M; Sonneveld, P; van Droogenbroeck, J; Wu, KL; Zweegman, S | 1 |
| Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS | 1 |
| Ardalan, B; Lima, M; Subbarayan, PR | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C | 1 |
| Falnoga, I; Podgornik, H; Pucer, A; Slejkovec, Z; Tusek-Znidaric, M | 1 |
| Bael, TE; Gollob, JA; Peterson, BL | 1 |
| Hu, J; Shu, C; Xu, W; Ye, Y | 1 |
| Ahuja, HG; Bailey, HH; Chang, JE; Kahl, BS; Kim, K; Kolesar, JM; Rodriguez, GA; Sanchez, FA; Voorhees, PM; Werndli, J | 1 |
| Grzanka, A; Izdebska, M; Litwiniec, A; Szczepański, MA | 1 |
| Alousi, A; Anderlini, P; Champlin, RE; Giralt, S; Hosing, C; Jones, RB; Khan, FB; Mendoza, F; Nieto, Y; Parikh, G; Pelosini, M; Popat, U; Qazilbash, MH; Saliba, RM; Wang, M; Weber, DM | 1 |
| Corti, A; Favini, E; Giommarelli, C; Paolicchi, A; Pompella, A; Supino, R; Zunino, F | 1 |
| Hong, Y; Li, S; Liu, P; Piao, F; Wang, Y; Zhao, Y | 1 |
| Bhadauria, S; Prathapan, A; Raghu, KG; Sharma, S; Singh, R; Yadav, GK | 1 |
| Biswas, S; Byrd, JC; Jarjoura, D; Mo, X; Mone, AP; Muthusamy, N; Vargo, M; Zhao, X | 1 |
| Rana, SV; Singh, S | 1 |
| Chan, SY; Ho, PC; Ong, PS | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Falnoga, I; Slejkovec, Z; van Elteren, JT; Zelenik Pevec, A | 1 |
| Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M | 1 |
| Au, WY; Kumana, CR; Kwong, YL; Lau, JS; Lee, HK; Lin, SY; Liu, H; Yeung, DY | 1 |
| Advani, A; Bejanyan, N; Chan, J; Jankowska, A; Kalaycio, M; Maciejewski, JP; Mooney, L; Raza, A; Saunthararajah, Y; Sekeres, MA; Tiu, RV | 1 |
| Park, WH; You, BR | 1 |
| Cilloni, D; Galimberti, S; Gioia, D; Guerrini, F; Levis, A; Messa, E; Palumbo, GA; Petrini, I; Petrini, M; Salvi, F | 1 |
| Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D | 1 |
| Dey, A; Mukherjee, S; Mukhopadhyay, PK; Pradhan, NK | 1 |
| Brandt-Rauf, P; Cassai, N; Dinnen, RD; Fine, RL; Mao, Y; Nichols, G; Qiu, W; Slavkovich, VN; Su, GH | 1 |
| Aldoss, I; Douer, D; Mark, L; Mohrbacher, AM; Ramezani, L; Vrona, J; Weitz, I | 1 |
| Chen, TY; Chen, ZG; Gao, X; Huang, CW; Huang, XC; Li, ZB; Maimaiti, XY; Zhang, L | 1 |
| Angelini, DF; Battistini, L; Berardi, A; Castelli, G; Catalano, G; Cicconi, L; D'Angiò, A; Fioritoni, G; Graziani, G; Guerrera, G; Lo-Coco, F; Massai, L; Mastrangelo, D; Noguera, NI; Pasquini, L; Pelosi, E; Piras, E; Piredda, ML; Testa, U; Voso, MT | 1 |
| Arathi, P; Binu, P; Nair, RH; Vineetha, RC | 1 |
| Au, WY; Chan, TSY; Gill, H; Hwang, YY; Ip, HW; Kho, B; Kumana, CR; Kwong, YL; Lau, JSM; Lee, HKK; Li, W; Lin, SY; Mak, V; Tse, E; Yim, R; Yip, SF | 1 |
| Bersimbaev, RI; Bhattacharya, R; Ellis, L; Hung, MC; Lee, MG; Lin, HK; Park, M; Peterson, CB; Sarbassov, DD; Sarbassova, DA; Song, MS; Wu, X; Ying, H | 1 |
| Begimbetova, D; Burska, AN; Dildabek, A; Ilyassova, B; Khamijan, M; Molnár, F; Sarbassov, DD | 1 |
| Aitbayev, C; Batyrbekov, K; Begimbetova, D; Burska, AN; Fazyl, F; Gulyayev, A; Khamijan, M; Kukanova, A; Makishev, A; Manekenova, K; Omarov, T; Saliev, T; Sarbassov, D; Spatayev, Z; Yermekbayeva, B | 1 |
6 review(s) available for arsenic trioxide and ascorbic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of re
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Clinical Trials as Topic; Drug Combinations; Glutathione; Humans; Mitochondria; Multiple Myeloma; Oxides; Reactive Oxygen Species | 2002 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Division; Clinical Trials as Topic; Dexamethasone; DNA-Binding Proteins; Drug Therapy, Combination; Glutathione; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Proto-Oncogenes; Transcription Factors | 2005 |
Oxidative stress and apoptosis: a new treatment paradigm in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Dose-Response Relationship, Drug; Glutathione; Hexanones; Humans; Metalloporphyrins; Models, Biological; Models, Chemical; Neoplasms; Oxidation-Reduction; Oxidative Stress; Oxides; Reactive Oxygen Species | 2006 |
[Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Drug Therapy, Combination; Glutathione; Humans; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; Neoplasms; NF-kappa B; Oxides; Tretinoin | 2008 |
Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.
Topics: Arsenic Trioxide; Ascorbic Acid; Cell Line, Tumor; Humans; Neoplasms; Oxidation-Reduction; Oxidative Stress; Proto-Oncogene Proteins p21(ras); Reactive Oxygen Species; Vitamins | 2022 |
17 trial(s) available for arsenic trioxide and ascorbic acid
| Article | Year |
|---|---|
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Resistance, Neoplasm; Feasibility Studies; Female; Glutathione; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Treatment Outcome | 2002 |
Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C).
Topics: Aged; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Division; Cell Line, Tumor; Clone Cells; Drug Synergism; Humans; Leukocytes, Mononuclear; Lymphoma, T-Cell, Cutaneous; Middle Aged; Mitochondria; Oxides; Skin Neoplasms | 2003 |
A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease Progression; Drug Resistance, Neoplasm; Humans; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2004 |
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Vitamins | 2006 |
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Creatinine; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Survival Analysis; Treatment Outcome | 2006 |
Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Humans; Middle Aged; Multiple Myeloma; Oxides; Recurrence | 2006 |
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome | 2007 |
Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Colorectal Neoplasms; DNA Primers; Gene Expression Regulation; Humans; Middle Aged; Neoplasm Metastasis; Oxides; Thymidylate Synthase; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Temozolomide | 2008 |
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Glutathione; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oxides; Safety | 2009 |
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Oxides; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult | 2011 |
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning | 2012 |
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cytarabine; Daunorubicin; Disease-Free Survival; Dyspepsia; Female; Follow-Up Studies; Headache; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2011 |
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Myelodysplastic-Myeloproliferative Diseases; Oxides; Primary Myelofibrosis; Thalidomide | 2012 |
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence | 2013 |
Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2014 |
33 other study(ies) available for arsenic trioxide and ascorbic acid
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cells, Cultured; Drug Synergism; Glutathione; Growth Inhibitors; Hematopoietic Stem Cells; HL-60 Cells; Humans; Lymphoma; Mice; Mice, Inbred Strains; Oxidation-Reduction; Oxides; Tumor Cells, Cultured | 1999 |
Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Synergism; Drug Therapy, Combination; Humans; In Situ Nick-End Labeling; Leukemia, Myeloid; Middle Aged; Oxides; Tumor Cells, Cultured | 2001 |
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Death; Drug Synergism; Glutathione; Humans; Hydrogen Peroxide; Multiple Myeloma; Oxides; Plasma Cells; Superoxides; Tumor Cells, Cultured | 2001 |
In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Mice; Mice, Transgenic; Models, Animal; Oxides; Proto-Oncogene Proteins; Survival Rate; Tumor Cells, Cultured | 2002 |
[Ascorbic acid enhances the apoptosis of U937 cells induced by arsenic trioxide in combination with DMNQ and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Synergism; Flow Cytometry; Humans; Naphthoquinones; Oxides; U937 Cells | 2002 |
Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide.
Topics: Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Bone Marrow Cells; Enzyme Activation; Enzyme Inhibitors; Growth Inhibitors; Humans; Imidazoles; Isoenzymes; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; rac1 GTP-Binding Protein; Tumor Cells, Cultured | 2002 |
Clinical activity of arsenic trioxide in Burkitt-like lymphoma.
Topics: Acute Disease; Adult; Antigens, CD; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Burkitt Lymphoma; Drug Therapy, Combination; Female; Humans; L-Lactate Dehydrogenase; Leukemia, Lymphoid; Oxides; Salvage Therapy; Treatment Outcome | 2003 |
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cyclooxygenase 2; DNA; Down-Regulation; Electrophoretic Mobility Shift Assay; Glutathione; HL-60 Cells; Humans; Hydrogen Peroxide; Isoenzymes; Leukemia, Myeloid, Acute; Membrane Proteins; NF-kappa B; Oxides; Prostaglandin-Endoperoxide Synthases; Protein Subunits; Superoxides; Tosylphenylalanyl Chloromethyl Ketone; Transcription Factor RelA | 2004 |
Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Treatment Outcome | 2005 |
Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Free Radical Scavengers; Humans; Liver Neoplasms; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2006 |
The effect of intracellular ascorbate on the susceptibility of HL60 and Jurkat cells to chemotherapy agents.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Count; Dehydroascorbic Acid; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Jurkat Cells; Melphalan; Oxides | 2006 |
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays | 2007 |
Arsenic metabolism in multiple myeloma and astrocytoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Astrocytoma; Biotransformation; Bone Marrow Cells; Cell Line, Tumor; Chromatography, Ion Exchange; Humans; Models, Chemical; Multiple Myeloma; Oxides; Reactive Oxygen Species; Time Factors | 2007 |
[Effects of vitamin C combined with arsenic trioxide on the apoptosis of Hep-2 cell].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Line, Tumor; Drug Synergism; Humans; Oxides | 2008 |
Gamma-glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by ascorbic acid.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Catalase; Cell Line, Tumor; Cytoprotection; Drug Resistance, Neoplasm; Enzyme Activation; gamma-Glutamyltransferase; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; MAP Kinase Kinase Kinase 5; Melanoma; Oxidative Stress; Oxides | 2009 |
Subchronic exposure to arsenic decreased Sdha expression in the brain of mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; ATP Synthetase Complexes; Brain; Computational Biology; Cytochromes c; Deoxyguanosine; Dose-Response Relationship, Drug; Electron Transport; Electron Transport Chain Complex Proteins; Electron Transport Complex III; Electron Transport Complex IV; Gene Expression Profiling; Gene Expression Regulation; Growth Inhibitors; Mice; Oligonucleotide Array Sequence Analysis; Oxides; Succinate Dehydrogenase; Taurine | 2009 |
Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
Topics: Action Potentials; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dose-Response Relationship, Drug; Drug Antagonism; Edema, Cardiac; Guinea Pigs; Heart; Leukemia, Promyelocytic, Acute; Male; Membrane Transport Modulators; Myocardium; Oxidants; Oxides; Oxidoreductases; Vasodilator Agents | 2009 |
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.
Topics: Amino Acid Chloromethyl Ketones; Amitrole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Ascorbic Acid; B-Lymphocytes; Buthionine Sulfoximine; Catalase; Cell Line, Tumor; Cysteine Proteases; Cysteine Proteinase Inhibitors; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Activation; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Oxidants; Oxidative Stress; Oxides; Reactive Oxygen Species | 2010 |
Ascorbic acid improves mitochondrial function in liver of arsenic-treated rat.
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Animals; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspase 3; Dose-Response Relationship, Drug; Histocytochemistry; Liver; Male; Mitochondria, Liver; Oxidative Phosphorylation; Oxides; Rats; Rats, Wistar; Succinate Dehydrogenase | 2010 |
Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Fibroblasts; Glutathione; Glutathione Peroxidase; Humans; Intracellular Space; Ovarian Neoplasms; Oxidative Stress; Oxides | 2011 |
As(2)O (3) oxidation by vitamin C: cell culture studies.
Topics: Animals; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Arsenites; Ascorbic Acid; Cattle; Cell Culture Techniques; Cell Line, Tumor; Culture Media; Oxidation-Reduction; Oxides | 2012 |
Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Fibroblasts; Glutathione; Humans; Lung; Oxides; Reactive Oxygen Species; Transfection | 2012 |
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.
Topics: Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Gene Expression; Genes, bcl-2; Humans; Male; Myelodysplastic Syndromes; Oxides; Real-Time Polymerase Chain Reaction | 2012 |
The effect of coadministration of α-tocopherol and ascorbic acid on arsenic trioxide-induced testicular toxicity in adult rats.
Topics: alpha-Tocopherol; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; DNA Damage; Drug Synergism; Drug Therapy, Combination; Endocrine Disruptors; Male; Oxidative Stress; Oxides; Rats; Rats, Wistar; Spermatogenesis; Testis; Testosterone | 2013 |
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Line, Tumor; Disease Models, Animal; Disulfiram; Dose-Response Relationship, Drug; Heterografts; Humans; Male; Mice; Necrosis; Oxides; Pancreatic Neoplasms; Reactive Oxygen Species; Tumor Stem Cell Assay; Voltage-Dependent Anion Channels | 2013 |
Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Bone Neoplasms; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Osteosarcoma; Oxides; Systems Biology | 2014 |
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Survival Analysis; Tumor Cells, Cultured | 2017 |
L-ascorbic acid and α-tocopherol attenuate arsenic trioxide-induced toxicity in H9c2 cardiomyocytes by the activation of Nrf2 and Bcl2 transcription factors.
Topics: alpha-Tocopherol; Animals; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cardiotoxicity; Cell Line; Cytoprotection; Heart Diseases; Membrane Potential, Mitochondrial; Mitochondria, Heart; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2; Rats; Signal Transduction | 2018 |
Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ascorbic Acid; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease-Free Survival; Female; Headache; Hematopoietic Stem Cell Transplantation; Hong Kong; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Risk Factors; Severity of Illness Index; Survival Analysis; Time Factors; Transplantation, Autologous; Tretinoin; Young Adult | 2018 |
A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Ascorbic Acid; Drug Synergism; HCT116 Cells; Humans; Isomerism; Mice, Nude; Mutation; Neoplasms, Experimental; Oxidative Stress; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2020 |
The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth.
Topics: Animals; Arsenic Trioxide; Ascorbic Acid; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Combinations; Humans; Mice; Oxidation-Reduction; Oxidative Stress; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |